Huihe Medical's Sci-Tech Innovation Board IPO Application Accepted by SSE
H&H Healthcare
R&D and Producer of Interventional Medical Devices for Heart Disease
Pioneer in Medical Device Media Coverage
Sharing Professional Medical Device Knowledge
According to the official website of the Shanghai Stock Exchange, on June 30, the initial public offering (IPO) application of Shanghai H&H Healthcare Technology Company Ltd. (hereinafter referred to as “H&H Healthcare”) for listing on the STAR Market was accepted.
It is reported that H&H Healthcare is primarily engaged in the field of pan-vascular intervention.Innovative HealthcareIn the research and development, manufacturing, and sales of medical devices, the company has, in recent years, established a comprehensive product portfolio in the field of pan-vascular intervention, including the K-Clip® Transcatheter Tricuspid Annuloplasty System, the C-Wave® Intravascular Shockwave Catheter, and Vispearl Polyvinyl Alcohol Embolization Microspheres.
In this IPO attempt, H&H Healthcare plans to raise RMB 1.11 billion.